文献速递妇科肿瘤

基于细胞学和高危人乳头瘤病毒优化早期宫颈癌保留生育功能手术后的随访策略:一项全国性、基于人群的回顾性队列研究

Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study.
PubMed 文献 · Lancet Oncol · 2023-11-09

该全国性回顾性队列研究纳入2000年至2020年荷兰1462例接受保留生育功能手术的早期宫颈癌患者,评估宫颈细胞学和高危HPV检测对复发性CIN2+的预测价值。中位随访6.1年,复发性CIN2+累积发生率15.0%,复发性宫颈癌5.4%。高危HPV阴性且细胞学正常或低级别者6-24个月复发累积发生率0.0-0.7%。

要点

  • 高危HPV阴性且细胞学正常或低级别者,术后6-24个月可延长随访间隔至6个月。
  • 连续两次高危HPV阴性且无高级别细胞学,12个月随访间隔似乎安全。
  • 高危HPV阳性且高级别细胞学者复发累积发生率达50.0-100.0%。

核心结论

  • 保留生育功能手术后6-24个月,高危HPV阴性且细胞学正常或低级别的患者可延长随访间隔至6个月,该组占所有接受保留生育功能手术患者的80%。
  • 连续两次高危HPV阴性且无高级别细胞学后,12个月随访间隔似乎安全,该组占近75%接受保留生育功能手术的患者。

研究设计与样本

  • 全国性、基于人群的回顾性队列研究,使用荷兰癌症登记处和荷兰全国病理数据库数据。
  • 纳入2000年1月1日至2020年12月31日期间年龄18-40岁、任何组织学类型、接受保留生育功能手术(即转化区大环切除术、锥切术或子宫颈切除术)的宫颈癌患者。
  • 共识别1548例患者,其中1462例符合纳入标准,可用19568份病理报告。

主要发现

  • 诊断时中位年龄31岁(IQR 30-35),中位随访6.1年(IQR 3.3-10.8)后,128例诊断为复发性CIN2+,累积发生率15.0%(95% CI 11.5-18.2),其中52例为复发性宫颈癌,累积发生率5.4%(95% CI 3.7-7.0)。
  • CIN2+总体10年无复发生存率为89.3%(95% CI 87.4-91.3)。
  • 首次随访(术后12个月内)细胞学正常者10年无复发生存率为92.1%(95% CI 90.2-94.1),低级别细胞学者为84.6%(95% CI 77.4-92.3),高级别细胞学者为43.1%(95% CI 26.4-70.2)。
  • 首次随访(术后12个月内)高危HPV阴性者10年无复发生存率为91.1%(95% CI 85.3-97.3),高危HPV阳性者为73.6%(95% CI 58.4-92.8)。
  • 任何随访(6-24个月)后6个月内,高危HPV阴性且细胞学正常或低级别者复发性CIN2+累积发生率为0.0-0.7%,高级别细胞学者为0.0-33.3%;高危HPV阳性且细胞学正常或低级别者为0.0-15.4%,高级别细胞学者为50.0-100.0%。

关键数值与推荐

  • 高危HPV阴性且细胞学正常或低级别者,术后6-24个月复发性CIN2+累积发生率为0.0-0.7%。
  • 高危HPV阳性且高级别细胞学者,术后6-24个月复发性CIN2+累积发生率为50.0-100.0%。
  • 高危HPV阴性且无高级别细胞学者,在6个月和12个月时均未发生复发。

临床怎么用

  • 作者认为,保留生育功能手术后6-24个月,高危HPV阴性且细胞学正常或低级别的患者可延长随访间隔至6个月。
  • 作者认为,连续两次高危HPV阴性且无高级别细胞学后,12个月随访间隔似乎安全。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal follow-up strategy to detect recurrence after fertility-sparing surgery for early stage cervical cancer is unknown. Tailored surveillance based on individual risks could contribute to improved efficiency and, subsequently, reduce costs in health care. The aim of this study was to establish the predictive value of cervical cytology and high-risk human papillomavirus (HPV) testing to detect recurrent cervical intraepithelial neoplasia grade 2 or worse (CIN2+; including recurrent cervical cancer) after fertility-sparing surgery. METHODS: In this nationwide, population-based, retrospective cohort study, we used data from the Netherlands Cancer Registry and the Dutch Nationwide Pathology Databank. All patients aged 18-40 years with cervical cancer of any histology who received fertility-sparing surgery (ie, large loop excision of the transformation zone, conisation, or trachelectomy) between Jan 1, 2000, and Dec 31, 2020, were included. Pathology data from diagnosis, treatment, and during follow-up were analysed. The primary and secondary outcomes were the cumulative incidence of recurrent CIN2+ and recurrence-free survival, overall and stratified by results for cytology and high-risk HPV. FINDINGS: 1548 patients were identified, of whom 1462 met the inclusion criteria. Of these included patients, 19 568 pathology reports were available. The median age at diagnosis was 31 years (IQR 30-35). After a median follow-up of 6·1 years (IQR 3·3-10·8), recurrent CIN2+ was diagnosed in 128 patients (cumulative incidence 15·0%, 95% CI 11·5-18·2), including 52 patients (cumulative incidence 5·4%, 95% CI 3·7-7·0) with recurrent cervical cancer. The overall 10-year recurrence-free survival for CIN2+ was 89·3% (95% CI 87·4-91·3). By cytology at first follow-up visit within 12 months after fertility-sparing surgery, 10-year recurrence-free survival for CIN2+ was 92·1% (90·2-94·1) in patients with normal cytology, 84·6% (77·4-92·3) in those with low-grade cytology, and 43·1% (26·4-70·2) in those with high-grade cytology. By high-risk HPV status at first follow-up visit within 12 months after surgery, 10-year recurrence-free survival for CIN2+ was 91·1% (85·3-97·3) in patients who were negative for high-risk HPV and 73·6% (58·4-92·8) in those who were positive for high-risk HPV. Cumulative incidence of recurrent CIN2+ within 6 months after any follow-up visit (6-24 months) in patients negative for high-risk HPV with normal or low-grade cytology was 0·0-0·7% and with high-grade cytology was 0·0-33·3%. Cumulative incidence of recurrence in patients positive for high-risk HPV with normal or low-grade cytology were 0·0-15·4% and with high-grade cytology were 50·0-100·0%. None of the patients who were negative for high-risk HPV without high-grade cytology, at 6 months and 12 months, developed recurrence. INTERPRETATION: Patients who are negative for high-risk HPV with normal or low-grade cytology at 6-24 months after fertility-sparing surgery, could be offered a prolonged follow-up interval of 6 months. This group comprises 80% of all patients receiving fertility-sparing surgery. An interval of 12 months seems to be safe after two consecutive negative tests for high-risk HPV with an absence of high-grade cytology, which accounts for nearly 75% of all patients who receive fertility-sparing surgery. FUNDING: KWF Dutch Cancer Society.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Schuurman TN, Schaafsma M, To KH, et al. Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study. Lancet Oncol. 2023. PMID: 37952541. doi:10.1016/S1470-2045(23)00467-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。